Cargando…

Encapsulated Carbenoxolone Reduces Lung Metastases

Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxol...

Descripción completa

Detalles Bibliográficos
Autores principales: Karsch-Bluman, Adi, Avraham, Shimrit, Assayag, Miri, Schwob, Ouri, Benny, Ofra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771083/
https://www.ncbi.nlm.nih.gov/pubmed/31533288
http://dx.doi.org/10.3390/cancers11091383
_version_ 1783455621687803904
author Karsch-Bluman, Adi
Avraham, Shimrit
Assayag, Miri
Schwob, Ouri
Benny, Ofra
author_facet Karsch-Bluman, Adi
Avraham, Shimrit
Assayag, Miri
Schwob, Ouri
Benny, Ofra
author_sort Karsch-Bluman, Adi
collection PubMed
description Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxolone’s activity and localization in the lungs, thereby reducing the potential adverse side effects resulting from systemic exposure, we developed a poly(lactic-co-glycolic acid) (PLGA) slow-release system for pulmonary delivery which maintains drug activity in-vitro, as demonstrated in the anoikis assay. Both systemic and intranasal administrations of carbenoxolone effectively minimize metastatic formation in a lung colonization model in mice. Our results show a decrease in the metastatic burden in the lung tissue. Notably, the therapeutic effect of a single intranasal administration of 25 mg/kg carbenoxolone, in the form of drug-loaded particles, had a similar effect in reducing metastatic lesions in the lungs to that of a 10-fold dose of the free drug via intraperitoneal injections, three times per week over the course of four weeks. These data offer new means to potentiate the anti-cancer activity of carbenoxolone and simultaneously reduce the requirement for high dosage administration; the upshot substantially improves therapeutic effect and avoidance of side effects.
format Online
Article
Text
id pubmed-6771083
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67710832019-10-30 Encapsulated Carbenoxolone Reduces Lung Metastases Karsch-Bluman, Adi Avraham, Shimrit Assayag, Miri Schwob, Ouri Benny, Ofra Cancers (Basel) Article Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxolone’s activity and localization in the lungs, thereby reducing the potential adverse side effects resulting from systemic exposure, we developed a poly(lactic-co-glycolic acid) (PLGA) slow-release system for pulmonary delivery which maintains drug activity in-vitro, as demonstrated in the anoikis assay. Both systemic and intranasal administrations of carbenoxolone effectively minimize metastatic formation in a lung colonization model in mice. Our results show a decrease in the metastatic burden in the lung tissue. Notably, the therapeutic effect of a single intranasal administration of 25 mg/kg carbenoxolone, in the form of drug-loaded particles, had a similar effect in reducing metastatic lesions in the lungs to that of a 10-fold dose of the free drug via intraperitoneal injections, three times per week over the course of four weeks. These data offer new means to potentiate the anti-cancer activity of carbenoxolone and simultaneously reduce the requirement for high dosage administration; the upshot substantially improves therapeutic effect and avoidance of side effects. MDPI 2019-09-17 /pmc/articles/PMC6771083/ /pubmed/31533288 http://dx.doi.org/10.3390/cancers11091383 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Karsch-Bluman, Adi
Avraham, Shimrit
Assayag, Miri
Schwob, Ouri
Benny, Ofra
Encapsulated Carbenoxolone Reduces Lung Metastases
title Encapsulated Carbenoxolone Reduces Lung Metastases
title_full Encapsulated Carbenoxolone Reduces Lung Metastases
title_fullStr Encapsulated Carbenoxolone Reduces Lung Metastases
title_full_unstemmed Encapsulated Carbenoxolone Reduces Lung Metastases
title_short Encapsulated Carbenoxolone Reduces Lung Metastases
title_sort encapsulated carbenoxolone reduces lung metastases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771083/
https://www.ncbi.nlm.nih.gov/pubmed/31533288
http://dx.doi.org/10.3390/cancers11091383
work_keys_str_mv AT karschblumanadi encapsulatedcarbenoxolonereduceslungmetastases
AT avrahamshimrit encapsulatedcarbenoxolonereduceslungmetastases
AT assayagmiri encapsulatedcarbenoxolonereduceslungmetastases
AT schwobouri encapsulatedcarbenoxolonereduceslungmetastases
AT bennyofra encapsulatedcarbenoxolonereduceslungmetastases